Asset sale Announced
Dimerix acquisition of MTX652
US$292m consideration
Announced Jul 2026 (approx.)
Advisers
Dimerix
Acquirer
Not disclosed
- Target
- MTX652
- Acquirer
- Dimerix
- Seller
- Mission Therapeutics
- Target based in
- United Kingdom (unverified)
- Buyer based in
- Australia
- Seller based in
- United Kingdom
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Gyre Therapeutics acquisition of Cullgen Mar 2026 · A$422m · Biotech
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · A$426m · Biotech
- Bayer acquisition of Perfuse Therapeutics May 2026 · A$420m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · A$388m · Biotech
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · A$525m · Biotech
Sources
- Jul 2026 Guggenheim Securities: Exclusive Financial Advisor to Mission Therapeutics on its Sale of MTX652 to Dimerix guggenheimsecurities.com